Publication:

Nek4 Regulates Entry into Replicative Senescence and the Response to DNA Damage in Human Fibroblasts

Loading...
Thumbnail Image

Date

2012

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

American Society for Microbiology
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Nguyen, C. L., R. Possemato, E. L. Bauerlein, A. Xie, R. Scully, and W. C. Hahn. 2012. “Nek4 Regulates Entry into Replicative Senescence and the Response to DNA Damage in Human Fibroblasts.” Molecular and Cellular Biology 32 (19): 3963–77. doi:10.1128/MCB.00436-12.

Abstract

When explanted into culture, normal human cells exhibit a finite number of cell divisions before entering a proliferative arrest termed replicative senescence. To identify genes essential for entry into replicative senescence, we performed an RNA interference (RNAi)-based loss-of-function screen and found that suppression of the Never in Mitosis Gene A (NIMA)-related protein kinase gene NEK4 disrupted timely entry into senescence. NEK4 suppression extended the number of population doublings required to reach replicative senescence in several human fibroblast strains and resulted in decreased transcription of the cyclin-dependent kinase inhibitor p21. NEK4-suppressed cells displayed impaired cell cycle arrest in response to double-stranded DNA damage, and mass spectrometric analysis of Nek4 immune complexes identified a complex containing DNA-dependent protein kinase catalytic subunit [DNA-PK(cs)], Ku70, and Ku80. NEK4 suppression causes defects in the recruitment of DNA-PK(cs) to DNA upon induction of double-stranded DNA damage, resulting in reduced p53 activation and H2AX phosphorylation. Together, these observations implicate Nek4 as a novel regulator of replicative senescence and the response to double-stranded DNA damage.

Description

Other Available Sources

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories